Experimental lymphoma drug shows early promise in tiny study
NCT ID NCT04676360
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a drug called belantamab mafodotin (Blenrep) in 10 people with rare, aggressive lymphomas that had come back or not responded to treatment. The drug is an antibody-drug conjugate designed to target and kill lymphoma cells. The trial was terminated early, so the full results are not available, but researchers were looking at how many patients responded and what side effects occurred.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- belantamab mafodotin (Blenrep)
- What this could lead to
- If successful, this could point toward a new treatment option for rare, aggressive lymphomas that have not responded to other therapies.
- What could go wrong
- This trial was terminated early and enrolled only 10 people, so results are very limited. The drug may cause side effects like eye problems, and it is unclear if it works better than existing options.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANAPLASTIC LYMPHOMA KINASE POSITIVE LARGE B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02115, United States
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.